Xconomy | Seattle - Business + Technology in the Exponential Economy

NanoString Nabs $30M in Third Venture Round (Which It Hopes Will Be The Last)
Lee Hood’s Proteges Strike Again: Nanostring Ships Its First Commercial Cell Analyzer
Clarus Leans on Customer Reviews at the Broad Institute to Bet on NanoString
Obama Stimulates UW, Public Biotechs Run Low on Cash, Healionics Ships Glaucoma Product & More Seattle-Area Life Sciences News
Dendreon’s Former Boss Predicts Takeover, Covance Buys Merck Lab, How NanoString Got $30M, & More Seattle-Area Life Sciences News

Nanostring CEO Perry Fell Departs

Nanostring Technologies CEO Perry Fell has resigned as CEO, and has been replaced on an acting basis by chief financial officer Wayne Burns. The Seattle-based company, which makes instruments that provide a digital readout for large-scale genomic experiments, shipped its first commercial product in July. The company was founded in 2004, and has raised $17 million from OVP Venture Partners and Draper Fisher Jurvetson. Fell will retain a board seat, said Sara Morris, a spokeswoman for OVP.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: